1. Field of the Invention
The present invention relates to medical devices, and more particularly to methods and apparatus for treating an abnormal vertebra. More particularly, an apparatus and method includes using a probe carrying a tissue-selective elastomeric rotational cutter having an abrasive surface for cutting a plane within vertebral cancellous bone to create a weakened plane.
2. Description of the Related Art
Osteoporotic fractures are prevalent in the elderly, with an annual estimate of 1.5 million fractures in the United States alone. These include 750,000 vertebral compression fractures (VCFs) and 250,000 hip fractures. The annual cost of osteoporotic fractures in the United States has been estimated at $13.8 billion. The prevalence of VCFs in women age 50 and older has been estimated at 26%. The prevalence increases with age, reaching 40% among 80-year-old women. Medical advances aimed at slowing or arresting bone loss from aging have not provided solutions to this problem. Further, the affected population will grow steadily as life expectancy increases. Osteoporosis affects the entire skeleton but most commonly causes fractures in the spine and hip. Spinal or vertebral fractures also have serious consequences, with patients suffering from loss of height, deformity and persistent pain which can significantly impair mobility and quality of life. Fracture pain usually lasts 4 to 6 weeks, with intense pain at the fracture site. Chronic pain often occurs when one level is greatly collapsed or multiple levels are collapsed.
Postmenopausal women are predisposed to fractures, such as in the vertebrae, due to a decrease in bone mineral density that accompanies postmenopausal osteoporosis. Osteoporosis is a pathologic state that literally means “porous bones”. Skeletal bones are made up of a thick cortical shell and a strong inner meshwork, or cancellous bone, of collagen, calcium salts and other minerals. Cancellous bone is similar to a honeycomb, with blood vessels and bone marrow in the spaces. Osteoporosis describes a condition of decreased bone mass that leads to fragile bones which are at an increased risk for fractures. In an osteoporotic bone, the sponge-like cancellous bone has pores or voids that increase in dimension, making the bone very fragile. In young, healthy bone tissue, bone breakdown occurs continually as the result of osteoclast activity, but the breakdown is balanced by new bone formation by osteoblasts. In an elderly patient, bone resorption can surpass bone formation thus resulting in deterioration of bone density. Osteoporosis occurs largely without symptoms until a fracture occurs.
Vertebroplasty and kyphoplasty are recently developed techniques for treating vertebral compression fractures. Percutaneous vertebroplasty was first reported by a French group in 1987 for the treatment of painful hemangiomas. In the 1990's, percutaneous vertebroplasty was extended to indications including osteoporotic vertebral compression fractures, traumatic compression fractures, and painful vertebral metastasis. In one percutaneous vertebroplasty technique, bone cement such as PMMA (polymethylmethacrylate) is percutaneously injected into a fractured vertebral body via a trocar and cannula system. The targeted vertebrae are identified under fluoroscopy. A needle is introduced into the vertebral body under fluoroscopic control to allow direct visualization. A transpedicular (through the pedicle of the vertebrae) approach is typically bilateral but can be done unilaterally. The bilateral transpedicular approach is typically used because inadequate PMMA infill is achieved with a unilateral approach.
In a bilateral approach, approximately 1 to 4 ml of PMMA are injected on each side of the vertebra. Since the PMMA needs to be forced into cancellous bone, the technique requires high pressures and fairly low viscosity cement. Since the cortical bone of the targeted vertebra may have a recent fracture, there is the potential of PMMA leakage. The PMMA cement contains radiopaque materials so that when injected under live fluoroscopy, cement localization and leakage can be observed. The visualization of PMMA injection and extravasion are critical to the technique—and the physician terminates PMMA injection when leakage is evident. The cement is injected using small syringe-like injectors to allow the physician to manually control the injection pressures.
Kyphoplasty is a modification of percutaneous vertebroplasty. Kyphoplasty involves a preliminary step that comprises the percutaneous placement of an inflatable balloon tamp in the vertebral body. Inflation of the balloon creates a cavity in the bone prior to cement injection. Further, the proponents of percutaneous kyphoplasty have suggested that high pressure balloon-tamp inflation can at least partially restore vertebral body height. In kyphoplasty, it has been proposed that PMMA can be injected at lower pressures into the collapsed vertebra since a cavity exists to receive the cement—which is not the case in conventional vertebroplasty.
The principal indications for any form of vertebroplasty are osteoporotic vertebral collapse with debilitating pain. Radiography and computed tomography must be performed in the days preceding treatment to determine the extent of vertebral collapse, the presence of epidural or foraminal stenosis caused by bone fragment retropulsion, the presence of cortical destruction or fracture and the visibility and degree of involvement of the pedicles. Leakage of PMMA during vertebroplasty can result in very serious complications including compression of adjacent structures that necessitate emergency decompressive surgery.
Leakage or extravasion of PMMA is a critical issue and can be divided into paravertebral leakage, venous infiltration, epidural leakage and intradiscal leakage. The exothermic reaction of PMMA carries potential catastrophic consequences if thermal damage were to extend to the dural sac, cord, and nerve roots. Surgical evacuation of leaked cement in the spinal canal has been reported. It has been found that leakage of PMMA is related to various clinical factors such as the vertebral compression pattern, and the extent of the cortical fracture, bone mineral density, the interval from injury to operation, the amount of PMMA injected and the location of the injector tip. In one recent study, close to 50% of vertebroplasty cases resulted in leakage of PMMA from the vertebral bodies. See Hyun-Woo Do et al, “The Analysis of Polymethylmethacrylate Leakage after Vertebroplasty for Vertebral Body Compression Fractures”, Jour. of Korean Neurosurg. Soc. Vol. 35, No. 5 (May 2004) pp. 478-82, (http://www.jkns.or.kr/htm/abstract.asp?no=0042004086).
Another recent study was directed to the incidence of new VCFs adjacent to the vertebral bodies that were initially treated. Vertebroplasty patients often return with new pain caused by a new vertebral body fracture. Leakage of cement into an adjacent disc space during vertebroplasty increases the risk of a new fracture of adjacent vertebral bodies. See Am. J. Neuroradiol. 2004 February; 25(2): 175-80. The study found that 58% of vertebral bodies adjacent to a disc with cement leakage fractured during the follow-up period compared with 12% of vertebral bodies adjacent to a disc without cement leakage.
Another life-threatening complication of vertebroplasty is pulmonary embolism. See Bernhard, J. et al., “Asymptomatic diffuse pulmonary embolism caused by acrylic cement: an unusual complication of percutaneous vertebroplasty”, Ann. Rheum. Dis. 2003; 62:85-86. The vapors from PMMA preparation and injection are also cause for concern. See Kirby, B., et al., “Acute bronchospasm due to exposure to polymethylmethacrylate vapors during percutaneous vertebroplasty”, Am. J. Roentgenol. 2003; 180:543-544.
Another disadvantage of PMMA is its inability to undergo remodeling—and the inability to use the PMMA to deliver osteoinductive agents, growth factors, chemotherapeutic agents and the like. Yet another disadvantage of PMMA is the need to add radiopaque agents which lower its viscosity with unclear consequences on its long-term endurance.
In both higher pressure cement injection (vertebroplasty) and balloon-tamped cementing procedures (kyphoplasty), the methods do not provide for well controlled augmentation of vertebral body height. The direct injection of bone cement simply follows the path of least resistance within the fractured bone. The expansion of a balloon also applies compacting forces along lines of least resistance in the collapsed cancellous bone. Thus, the reduction of a vertebral compression fracture is not optimized or controlled in high pressure balloons as forces of balloon expansion occur in multiple directions.
In a kyphoplasty procedure, the physician often uses very high pressures (e.g., up to 200 or 300 psi) to inflate the balloon which first crushes and compacts cancellous bone. Expansion of the balloon under high pressures close to cortical bone can fracture the cortical bone, or cause regional damage to the cortical bone that can result in cortical bone necrosis. Such cortical bone damage is highly undesirable and results in weakened cortical endplates.
Kyphoplasty also does not provide a distraction mechanism capable of 100% vertebral height restoration. Further, the kyphoplasty balloons under very high pressure typically apply forces to vertebral endplates within a central region of the cortical bone that may be weak, rather than distributing forces over the endplate.
There is a general need to provide systems and methods for use in treatment of vertebral compression fractures that provide a greater degree of control over introduction of bone support material, and that provide better outcomes. Embodiments of the present invention meet one or more of the above needs, or other needs, and provide several other advantages in a novel and non-obvious manner.
The invention provides systems and methods for treatment of vertebral compression fractures as well as systems and methods for prophylactic treatment of osteoporotic vertebrae in subjects having vertebrae that are susceptible to a compression fracture. The invention also can be used in correcting and supporting bones in other abnormalities such as bone tumors and cysts, avascular necrosis of the femoral head and tibial plateau fractures.
In one embodiment, a probe system is provided that has a working end comprising an elastomeric abrasive cutter that is rotated at high speeds by a motor drive. The rotational elastomeric abrader has a tissue-selective abrading surface that within a selective rpm range can abrade or cut cancellous bone or cortical bone but will not cut soft tissue. The system is used for abrading or cutting at least one path or space within vertebral cancellous bone. Irrigation and aspiration sources are included in the probe system for removing abraded bone debris. After the creation of a path or space in bone, an in-situ hardenable bone cement volume is introduced into each path or space to support the vertebra.
In another embodiment of the invention, a probe system has a working end that comprises an expandable structure having an abrasive surface. In use, the expandable abrading surface is rotated at high speed to cut bone while being expanded to increase the cross section of the path or space being created. The use of the expandable cutter allows the treatment of bone with low pressures to create paths or spaces without explosive expansion forces known in prior art balloon procedures that are designed to crush and compact cancellous bone in a vertebra.
There is a general need to provide systems and methods for use in treatment of vertebral compression fractures that provide a greater degree of control over introduction of bone support material, and that provide better outcomes. The present invention meets this need and provides several other advantages in a novel and nonobvious manner.
These and other objects of the present invention will become readily apparent upon further review of the following drawings and specification.
In order to better understand the invention and to see how it may be carried out in practice, some preferred embodiments are next described, by way of non-limiting examples only, with reference to the accompanying drawings, in which like reference characters denote corresponding features consistently throughout similar embodiments in the attached drawings.
In the embodiment of
In the embodiment of
The elastomeric cutter 112 can be operated within a selected speed range that preferentially abrades and cuts bone such as cancellous or cortical bone but will not abrade soft tissue. This aspect of the invention is useful, for example, in operations in the interior of a vertebral body, for example when cutting through a cortical wall and inadvertently contacting soft tissue outside the vertebra. The system will discriminate tissue density and not cut the lower density soft tissue such as ligaments. The use of a resilient cutter at selected speeds to discriminate in cutting harder tissue and sparing softer tissue was disclosed in U.S. Pat. Nos. 4,445,509 and 4,990,134 to David C. Auth, which are incorporated herein by this reference. The Auth patents relate to endovascular catheter tips that are abrasive for cutting occlusive materials that clog an artery. The present invention is fabricated in the configuration of a rigid probe 100 with dimensions suited for percutaneous insertion into an abnormal vertebra.
In one method of use shown in
In
In another embodiment similar to that of
The method of
In contrast, the method of the invention depicted in
In another aspect of the method of
In another aspect of the apparatus and method depicted in FIGS. 8 and 9A-9C, the system uses fluid expansion to move an expandable structure from a first transverse dimension to a second greater transverse dimension in cancellous bone of a vertebra at low non-explosive fluid inflow pressures while rotationally abrading the cancellous bone. The pressures can be less than 100 psi, or more preferably less than 50 psi, or more preferably less than 25 psi. The system pressures used by the inventive method are far lower than practiced in balloon procedures adapted to crush and compact cancellous bone.
In one aspect, a method of the invention comprises inserting an expandable structure into cancellous bone, and expanding the structure at a selected rate of expansion without compacting the cancellous bone by rotation of an abrasive surfaced structure to thereby cut bone. In another aspect of the invention, the method of the invention includes inserting an expandable structure into cancellous bone, and expanding the structure step-wise to insure that explosive expansion does not occur together with the rotational bone abrading step. In another aspect of the invention, the method includes inserting an expandable structure into cancellous bone, and expanding the structure with fluid inflow pulses that range from 1 Hz to 1,000 Hz to enhance bone abrasion with the surface of the expandable structure. More preferably, the fluid inflows are pulses in the range of 10 to 100 Hz.
In one aspect, the apparatus of the invention for abrading bone comprises (a) an elongated member having a first end and a second end, (b) the second end having an expandable cross-section with an abrasive surface, and (c) a rotational drive mechanism coupled to the first end for rotation thereof to abrade a path or a space in a bone. In an exemplary embodiment, the abrasive surface is a polymeric material with abrasive particles affixed thereto, such as diamond particles. The diamond particles can be natural monocrystalline diamond, synthetic monocrystalline diamond, polycrystalline diamond or a combination thereof. The diamond particles have a mean dimension ranging from about 1.0 micron to 100 microns.
In the embodiment of
In any of the above methods, the volume of bone cement volume can comprise a PMMA, monocalcium phosphate, tricalcium phosphate, calcium carbonate, calcium sulphate and hydroxyapatite, or any combination thereof. The bone cement also can carry allograft material, autograft material or any other infill bone infill granular material or scaffold material as in known in the art.
The above description of the invention intended to be illustrative and not exhaustive. A number of variations and alternatives will be apparent to one having ordinary skills in the art. Such alternatives and variations are intended to be included within the scope of the claims. Particular features that are presented in dependent claims can be combined and fall within the scope of the invention. The invention also encompasses embodiments as if dependent claims were alternatively written in a multiple dependent claim format with reference to other independent claims.
This application claims benefit of Provisional U.S. Patent Application Ser. No. 60/629,628 filed Nov. 19, 2004 titled Systems and Methods for Treating Vertebral Fractures. This application also is related to U.S. application Ser. No. 11/165,652 filed Jun. 24, 2005 titled Bone Treatment Systems and Methods; and U.S. patent application Ser. No. 11/165,651 filed Jun. 24, 2005, titled Bone Treatment Systems and Methods. The entire contents of all of the above cross-referenced applications are hereby incorporated by reference in their entirety and should be considered a part of this specification.
Number | Name | Date | Kind |
---|---|---|---|
3621505 | Vocker et al. | Nov 1971 | A |
4271839 | Fogarty et al. | Jun 1981 | A |
4294251 | Greenwald et al. | Oct 1981 | A |
4338925 | Miller | Jul 1982 | A |
4445509 | Auth | May 1984 | A |
4827676 | Kindermann | May 1989 | A |
4857045 | Rydell | Aug 1989 | A |
4895146 | Draenert | Jan 1990 | A |
4969888 | Scholten et al. | Nov 1990 | A |
4969906 | Kronman | Nov 1990 | A |
4990134 | Auth | Feb 1991 | A |
5059193 | Kuslich | Oct 1991 | A |
5108404 | Scholten | Apr 1992 | A |
5285795 | Ryan et al. | Feb 1994 | A |
5409376 | Murphy | Apr 1995 | A |
5431654 | Nic | Jul 1995 | A |
5679299 | Gilbert et al. | Oct 1997 | A |
5693099 | Harle | Dec 1997 | A |
5827289 | Reiley et al. | Oct 1998 | A |
5925038 | Panescu et al. | Jul 1999 | A |
5972015 | Scribner | Oct 1999 | A |
6048346 | Reiley | Apr 2000 | A |
6145833 | Rodewald et al. | Nov 2000 | A |
6171312 | Beaty | Jan 2001 | B1 |
6235043 | Reiley | May 2001 | B1 |
6248110 | Reiley et al. | Jun 2001 | B1 |
6261289 | Levy | Jul 2001 | B1 |
6280456 | Scribner | Aug 2001 | B1 |
6296639 | Truckai et al. | Oct 2001 | B1 |
6319255 | Grundei et al. | Nov 2001 | B1 |
6332894 | Stalcup et al. | Dec 2001 | B1 |
6358254 | Anderson | Mar 2002 | B1 |
6425923 | Stalcup et al. | Jul 2002 | B1 |
6439439 | Rickard | Aug 2002 | B1 |
6440138 | Reiley | Aug 2002 | B1 |
6443967 | Kadavy et al. | Sep 2002 | B1 |
6443988 | Felt et al. | Sep 2002 | B2 |
6447514 | Stalcup et al. | Sep 2002 | B1 |
6468289 | Bonutti | Oct 2002 | B1 |
6706069 | Berger | Mar 2004 | B2 |
6712852 | Chung et al. | Mar 2004 | B1 |
6716216 | Boucher | Apr 2004 | B1 |
6719773 | Boucher | Apr 2004 | B1 |
6719803 | Bonutti | Apr 2004 | B2 |
6723095 | Hammerslag | Apr 2004 | B2 |
6726691 | Osorio et al. | Apr 2004 | B2 |
6740093 | Hochschuler et al. | May 2004 | B2 |
6746451 | Middleton et al. | Jun 2004 | B2 |
6790210 | Cragg et al. | Sep 2004 | B1 |
6863672 | Reiley | Mar 2005 | B2 |
6923813 | Phillips | Aug 2005 | B2 |
6981981 | Reiley | Jan 2006 | B2 |
7044954 | Reiley | May 2006 | B2 |
7153306 | Ralph | Dec 2006 | B2 |
7156861 | Scribner | Jan 2007 | B2 |
7166121 | Reiley et al. | Jan 2007 | B2 |
7211085 | Michelson | May 2007 | B2 |
20010034526 | Kuslich et al. | Oct 2001 | A1 |
20020026195 | Layne et al. | Feb 2002 | A1 |
20020082608 | Reiley et al. | Jun 2002 | A1 |
20020099385 | Ralph et al. | Jul 2002 | A1 |
20020147497 | Belef et al. | Oct 2002 | A1 |
20020183758 | Middleton et al. | Dec 2002 | A1 |
20020188299 | Reiley et al. | Dec 2002 | A1 |
20030032929 | McGuckin | Feb 2003 | A1 |
20030097133 | Green et al. | May 2003 | A1 |
20030130664 | Boucher et al. | Jul 2003 | A1 |
20030195547 | Scribner et al. | Oct 2003 | A1 |
20030220648 | Osorio et al. | Nov 2003 | A1 |
20030233096 | Osorio et al. | Dec 2003 | A1 |
20040024410 | Olson, Jr. et al. | Feb 2004 | A1 |
20040073308 | Kuslich et al. | Apr 2004 | A1 |
20040092948 | Stevens et al. | May 2004 | A1 |
20040097946 | Dietzel et al. | May 2004 | A1 |
20040102845 | Reynolds | May 2004 | A1 |
20040138748 | Boyer, II et al. | Jul 2004 | A1 |
20040147934 | Kiester | Jul 2004 | A1 |
20040167561 | Boucher et al. | Aug 2004 | A1 |
20040168698 | Gueret | Sep 2004 | A1 |
20040186576 | Biscup et al. | Sep 2004 | A1 |
20040210231 | Boucher et al. | Oct 2004 | A1 |
20040225296 | Reiss et al. | Nov 2004 | A1 |
20040225926 | Scales | Nov 2004 | A1 |
20040267271 | Scribner et al. | Dec 2004 | A9 |
20040267272 | Henniges | Dec 2004 | A1 |
20050010231 | Myers | Jan 2005 | A1 |
20050015148 | Jansen et al. | Jan 2005 | A1 |
20050055785 | Spooner | Mar 2005 | A1 |
20050059979 | Yetkinler et al. | Mar 2005 | A1 |
20050203527 | Carrison et al. | Sep 2005 | A1 |
20050209595 | Karmon | Sep 2005 | A1 |
20050222681 | Richley et al. | Oct 2005 | A1 |
20050245938 | Kochan | Nov 2005 | A1 |
20060100635 | Reiley et al. | May 2006 | A1 |
20060100706 | Shadduck et al. | May 2006 | A1 |
20060229625 | Truckai et al. | Oct 2006 | A1 |
20070198020 | Reiley et al. | Aug 2007 | A1 |
20080208196 | Daum | Aug 2008 | A1 |
Number | Date | Country |
---|---|---|
1529494 | May 2005 | EP |
1787593 | May 2007 | EP |
WO 9106713 | May 1991 | WO |
Entry |
---|
Office Action in U.S. Appl. No. 11/271,498, mailed Oct. 27, 2008. |
Office Action in U.S. Appl. No. 11/271,498, mailed Jan. 22, 2008. |
Number | Date | Country | |
---|---|---|---|
20060149268 A1 | Jul 2006 | US |
Number | Date | Country | |
---|---|---|---|
60629628 | Nov 2004 | US |